Online inquiry

IVTScrip™ mRNA-Anti-EGFR, cetuximab-IR700(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ5773MR)

This product GTTS-WQ5773MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets EGFR gene. The antibody can be applied in Cancers research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Chimeric
RefSeq NM_001346897.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1956
UniProt ID Q504U8
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-EGFR, cetuximab-IR700(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ5773MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ11195MR IVTScrip™ mRNA-Anti-TNFRSF18, MEDI-1873(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA MEDI-1873
GTTS-WQ12719MR IVTScrip™ mRNA-Anti-DLL4&VEGFA, OMP-305B83(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA OMP-305B83
GTTS-WQ1586MR IVTScrip™ mRNA-Anti-MSTN, ACE-083(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA ACE-083
GTTS-WQ14531MR IVTScrip™ mRNA-Anti-IL13&IL4, SAR156597(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA SAR156597
GTTS-WQ11035MR IVTScrip™ mRNA-Anti-ERBB2&ERBB3, MCLA-128(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MCLA-128
GTTS-WQ12690MR IVTScrip™ mRNA-Anti-DLL4, OMP-21M18(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA OMP-21M18
GTTS-WQ10857MR IVTScrip™ mRNA-Anti-FOLR1, M9346A(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA M9346A
GTTS-WQ8222MR IVTScrip™ mRNA-Anti-KDR, HLX-06(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA HLX-06
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW